Autoimmune gastritis is a chronic condition in which the immune system attacks the acid- and intrinsic-factor-producing cells of the stomach, quietly leading to iron and vitamin B12 deficiency long before obvious symptoms appear. It returned to the headlines in July 2026, when longevity entrepreneur Bryan Johnson disclosed that, after roughly 11 years of unexplained low ferritin, an endoscopy with biopsies and antibody testing confirmed early-stage autoimmune gastritis. This timeline explains the disease using recognised clinical guidance, traces the science from the discovery of pernicious anaemia to modern diagnostics, and places Johnson’s case in context — keeping his personal experience clearly separate from general medical evidence.
Autoimmune gastritis (AIG) is a chronic disease in which the immune system destroys the stomach’s parietal cells, which make stomach acid and intrinsic factor. This reduces absorption of iron (often causing early iron deficiency) and vitamin B12 (which can later cause pernicious anaemia). It is often silent for years and shows up as fatigue or low iron on blood tests. Diagnosis uses blood tests, antibody tests and an upper endoscopy with biopsies. There is no cure, but it is managed by replacing iron and B12 and monitoring for complications, including a higher long-term risk of certain gastric tumours. In July 2026, Bryan Johnson disclosed an early-stage diagnosis after years of low ferritin — his individual case, not general medical advice.
Six clinical anchors (general information, not a diagnosis for any individual).
Mechanism
Statistics
Diagnosis
Complication
Treatment
Personal
Reverse chronological — latest first, the discovery of pernicious anaemia last.
Bryan Johnson’s personal account: the longevity entrepreneur publicly shared that he had been diagnosed with early-stage autoimmune gastritis. He reported roughly 11 years of chronically low ferritin while his haemoglobin and haematocrit stayed normal, and said a bi-directional endoscopy with biopsies from three regions of the stomach, plus elevated anti-parietal-cell antibodies (reported at 103 U/mL), confirmed early atrophy limited to the acid-producing lining.
Why it matters (editorial): his case illustrates how AIG can be caught early through long-term monitoring of iron markers — but it is one person’s medical journey, not evidence that any lifestyle causes or prevents the disease.
Clinical evidence: recent research continued refining non-invasive biomarkers — such as pepsinogen I, the pepsinogen I:II ratio and gastrin-17 — and H+/K+ ATPase antibody testing to improve early detection and risk stratification, alongside work on how best to time endoscopic surveillance for cancer risk.
Clinical evidence: gastroenterology guidance increasingly emphasised recognising AIG in people with unexplained iron or B12 deficiency, standardised biopsy protocols, and the value of AI-assisted digital pathology to help detect early atrophy and metaplasia consistently.
Clinical evidence: major reviews clarified the epidemiology, risk factors and management of autoimmune gastritis, with and without pernicious anaemia, and reinforced its links to other autoimmune conditions such as thyroid disease and type 1 diabetes. Awareness grew that iron deficiency — not just B12 — is often the first sign.
Clinical evidence: more specific antibody tests (against the H+/K+ ATPase proton pump) improved on older parietal-cell antibody assays, endoscopy and the updated Sydney biopsy system standardised assessment, and evidence solidified that AIG raises the risk of gastric neuroendocrine (carcinoid) tumours and adenocarcinoma, supporting surveillance.
Scientific milestone: researchers distinguished Type A (autoimmune, corpus-predominant) from Type B (H. pylori, antrum-predominant) gastritis in 1973. In 1982, Barry Marshall and Robin Warren discovered Helicobacter pylori (Nobel Prize 2005), transforming the understanding of gastritis and clarifying what autoimmune gastritis is — and is not.
Scientific foundation: Thomas Addison described pernicious anaemia in the mid-1800s. In the 1920s, liver therapy by Minot and Murphy (Nobel Prize 1934) transformed it from fatal to treatable; William Castle identified intrinsic factor in 1929; vitamin B12 was isolated in 1948 and its structure solved by Dorothy Hodgkin in 1956. These discoveries revealed the biology behind autoimmune gastritis decades before the disease was fully defined.
What happens: in autoimmune gastritis, immune cells and antibodies target the stomach’s parietal cells in the body and fundus. These cells make stomach acid and intrinsic factor. As they are destroyed, acid falls (hypochlorhydria or achlorhydria) and intrinsic factor drops. Low acid impairs iron absorption, so iron deficiency is often the earliest problem; loss of intrinsic factor impairs vitamin B12 absorption, which over time can cause pernicious anaemia and neurological symptoms. The antrum is usually spared, and low acid drives high gastrin, which can stimulate ECL-cell growth.
Symptoms: many people have no digestive symptoms for years. Early clues are usually from deficiency — fatigue, weakness and pallor from iron deficiency; later, numbness, tingling, balance problems or memory issues from B12 deficiency. Some report bloating or early fullness. Risk factors and associations include female sex, older age, a family or personal history of autoimmune disease (especially autoimmune thyroid disease, type 1 diabetes, vitiligo and Addison’s disease).
Causation caution (editorial): the exact trigger of autoimmune gastritis is not fully understood, and current evidence does not establish that specific diets, supplements or longevity routines cause or prevent it. Any individual case, including a public figure’s, should not be read as proof of a broader cause.
A combination of blood, antibody and endoscopic tests — interpreted by a clinician.
| Test | What it looks for |
|---|---|
| Ferritin & iron studies | Low iron stores, often the earliest sign (may precede anaemia) |
| Full blood count | Iron-deficiency or later megaloblastic (B12) anaemia |
| Vitamin B12 | Low B12 from loss of intrinsic factor |
| Parietal-cell antibodies | Positive in ~80% of AIG (also in some healthy people) |
| Intrinsic-factor antibodies | More specific for pernicious anaemia, but less sensitive |
| Gastrin & pepsinogens | High gastrin, low pepsinogen I and I:II ratio suggest corpus atrophy |
| Upper endoscopy | Direct view; targeted biopsies of body and antrum |
| Biopsy & histopathology | Confirms corpus-predominant atrophy and metaplasia — the gold standard |
There is no cure, but the condition is managed — always under a clinician’s guidance.
No treatment currently reverses the autoimmune process, and parietal-cell damage is generally not reversible. Management aims to correct deficiencies and reduce complications. Specific medicines, doses and monitoring schedules must be decided by a qualified healthcare professional for each person.
| Feature | Autoimmune (Type A) | H. pylori (Type B) |
|---|---|---|
| Cause | Immune attack on parietal cells | Bacterial infection |
| Main location | Body / fundus (corpus) | Antrum (can be multifocal) |
| Stomach acid | Low (achlorhydria) | Variable |
| Key deficiencies | Iron, then vitamin B12 | Iron; B12 less typical |
| Curable? | No cure; managed | Often curable with antibiotics |
| Cancer risk | Adenocarcinoma & carcinoid | Adenocarcinoma, MALT lymphoma |
The two can overlap, and H. pylori is sometimes proposed as a possible trigger of autoimmunity in some people, though this link is not fully settled. A clinician distinguishes them using antibody tests, biopsy location and H. pylori testing.
Autoimmune gastritis is associated with a higher long-term risk of two gastric tumours: type 1 neuroendocrine (carcinoid) tumours, driven by high gastrin from low acid, and gastric adenocarcinoma. Reviews describe roughly a threefold excess risk of adenocarcinoma and a much larger relative excess for carcinoid tumours, though absolute yearly risks are low (studies report on the order of a few percent per year for neuroendocrine tumours and well under one percent per year for gastric cancer). Because of this, guidelines support periodic endoscopic surveillance, with intervals individualised by a clinician based on biopsy findings and risk. These are population-level statistics, not a prediction for any single person.
| Myth | Fact |
|---|---|
| “Autoimmune gastritis is caused by a bad diet.” | It is an autoimmune condition; current evidence does not show that diet or lifestyle causes it. |
| “You would feel it if you had it.” | It is often silent for years, first appearing as fatigue or low iron on blood tests. |
| “It is the same as acid reflux or an ulcer.” | No. It is a distinct autoimmune atrophy of the stomach lining, not reflux or a simple ulcer. |
| “Only B12 matters.” | Iron deficiency is often the earliest problem, sometimes years before B12 falls. |
| “It can be cured with antibiotics.” | Antibiotics treat H. pylori, a different cause; autoimmune gastritis has no cure and is managed. |
The US National Institutes of Health funds and publishes research on autoimmune disease, anaemia and vitamin B12, underpinning much of what is known about AIG.
A leading source of patient-facing clinical guidance on gastritis, pernicious anaemia and B12 deficiency, widely used for evidence-based explanations.
Provides clinical information on autoimmune and digestive conditions, including diagnosis and management of atrophic gastritis.
Issues clinical guidance for gastroenterologists, including approaches to atrophic gastritis, biopsy protocols and surveillance.
Entrepreneur known for his longevity project; in July 2026 he disclosed an early-stage autoimmune gastritis diagnosis, raising public awareness. His case is personal, not general medical evidence.
A protein made by parietal cells that is essential for vitamin B12 absorption; its loss is central to pernicious anaemia in AIG.
The most-searched questions, answered with clinical evidence and clearly labelled personal context.
General medical information, not personalised advice. See a clinician for your situation.